On-site experience of a project to increase access to diagnosis and treatment of Chagas disease in high-risk endemic areas of Colombia

Acta Trop. 2022 Feb:226:106219. doi: 10.1016/j.actatropica.2021.106219. Epub 2021 Oct 29.

Abstract

Colombia has one of the largest burdens of Chagas disease globally, with about 438,000 people affected according to 2015 estimates. Despite this, < 1% of the population has had access to diagnosis and treatment. A patient-centered roadmap for Chagas disease was developed from 2015 onwards to address access barriers and increase diagnostic and therapeutic coverage and was implemented in five municipalities where Chagas disease is endemic. The mean number of people tested per year increased from 37 before the project to 262 following implementation, and the average days between medical order and diagnostic confirmation results decreased from 258 to 19. The mean days from diagnostic confirmation to treatment initiation decreased from 354 before the project to 135 after implementation. The 5,654 people tested included 3,467 women of childbearing age. The prevalence of T. cruzi infection was 11.5%, and thus far 266 people have received antitrypanosomal treatment. Collaborative creation and implementation of a patient-centered roadmap can address access barriers in specific contexts, helping to reduce the invisibility and burden of this neglected disease.

Keywords: Chagas disease; Health service accessibility; Neglected tropical diseases; Trypanosoma cruzi.

MeSH terms

  • Chagas Disease* / diagnosis
  • Chagas Disease* / drug therapy
  • Chagas Disease* / epidemiology
  • Colombia / epidemiology
  • Female
  • Humans
  • Prevalence
  • Trypanosoma cruzi*